Unique ID issued by UMIN | UMIN000011103 |
---|---|
Receipt number | R000013005 |
Scientific Title | The investigation of the tolerability and the cost, due to the drug change to novel oral anticoagurants (rivaroxaban) from warfarin in patients with nonvalvular atrial fibrillation in the perioperative period |
Date of disclosure of the study information | 2013/07/03 |
Last modified on | 2019/01/07 09:14:36 |
The investigation of the tolerability and the cost, due to the drug change to novel oral anticoagurants (rivaroxaban) from warfarin in patients with nonvalvular atrial fibrillation in the perioperative period
The investigation of the tolerability and the cost, due to the drug change to novel oral anticoagurants (rivaroxaban) from warfarin in patients with nonvalvular atrial fibrillation in the perioperative period
The investigation of the tolerability and the cost, due to the drug change to novel oral anticoagurants (rivaroxaban) from warfarin in patients with nonvalvular atrial fibrillation in the perioperative period
The investigation of the tolerability and the cost, due to the drug change to novel oral anticoagurants (rivaroxaban) from warfarin in patients with nonvalvular atrial fibrillation in the perioperative period
Japan |
Nonvalvular Atrial Fibrillation
Cardiology |
Others
NO
To investigate the tolerability and the cost affected by the oral anticoagurants change to Xarelto from warfarin in patients with nonvalvular atrial fibrillation in the perioperative period
Safety,Efficacy
1)Inpatient days
2)In-hospital medical expense (including outpatient therapy)
Tolerability (existence or nonexistence of hemorrhage and orischemic events)
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Xarelto is administered to patients at the dose of 15mg/day.
20 | years-old | <= |
Not applicable |
Male and Female
1)The patients with nonvalvular atrial fibrillation who are scheduled to undergo surgery recommended to use Heparin
2)Patients who received sufficient explanation before participation in this study, understood it and gave written consent based on their free will
1)The patients with contraindication of Xarelto
2)The patients who are not allowed to participate in the trial by the principal investigator
50
1st name | |
Middle name | |
Last name | Takahisa YAMADA |
Osaka General Medical Center
Division of Cardiology
3-1-56, Bandaihigashi, Sumiyoshi-ku, Osaka
06-6692-1201
kenkyusien@gh.opho.jp
1st name | |
Middle name | |
Last name | Takahisa YAMADA |
Osaka General Medical Center
Division of Cardiology
3-1-56, Bandaihigashi, Sumiyoshi-ku, Osaka
06-6692-1201
kenkyusien@gh.opho.jp
Osaka General Medical Center
None
Self funding
NO
2013 | Year | 07 | Month | 03 | Day |
Unpublished
Completed
2013 | Year | 06 | Month | 11 | Day |
2013 | Year | 07 | Month | 01 | Day |
2017 | Year | 03 | Month | 31 | Day |
2013 | Year | 07 | Month | 03 | Day |
2019 | Year | 01 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013005